Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for HIV patients: shorter, stronger fungal infection treatment on trial

NCT ID NCT06525389

First seen Jan 09, 2026 · Last updated Jun 17, 2026 · Updated 27 times

Summary

This study tests two new ways to treat talaromycosis, a serious fungal infection in people with HIV. It compares a single high dose of a newer antifungal drug (liposomal amphotericin B) against two weeks of the standard drug, and also checks if adding another medicine (flucytosine) helps. The trial will include 428 adults with HIV and confirmed talaromycosis. The goal is to find a more effective and simpler treatment to reduce deaths and complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TALAROMYCOSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bach Mai Hospital

    Hanoi, Vietnam

    Contact Email: •••••@•••••

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital for Tropical Diseases

    Ho Chi Minh City, 7000, Vietnam

    Contact

  • National Hospital for Tropical Diseases

    Hanoi, Vietnam

    Contact

  • Pham Ngoc Thach University of Medicine

    Ho Chi Minh City, 7000, Vietnam

    Contact

    Contact Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

penicilliosis talaromycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.